Junction vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 38)
Junction logo

Junction

EmergingHealthcare

General

US YC health data API infrastructure connecting 500+ wearables and at-home lab tests for 140+ healthcare orgs; $18M Creandum Series A Mar 2025 supporting 2M+ connected devices and 500K+ tests annually competing with Validic and Terra API.

AI VisibilityBeta
Overall Score
D38
Category Rank
#462 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
42
Perplexity
37
Gemini
42

About

Junction is a United States-based health data infrastructure company — backed by Y Combinator with $18 million in Series A funding in March 2025 led by Creandum with participation from Point Nine, Amino Collective, and Inflect Health — providing digital health companies, research organizations, and healthcare technology platforms with a unified API infrastructure for collecting wearable device data (500+ supported devices including Apple Watch, Fitbit, Oura, Garmin, and continuous glucose monitors) and delivering at-home diagnostic test kits to patients with automated diagnostic data workflows that connect labs, wearables, and health systems. Founded and serving 140+ healthcare organizations including Found, Parsley Health, and Evidation, Junction supports 500,000+ lab tests annually and 2 million+ connected devices.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

38
Overall Score
93
#462
Category Rank
#1
81
AI Consensus
80
stable
Trend
stable
42
ChatGPT
94
37
Perplexity
89
42
Gemini
94
35
Claude
92
39
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.